Wayne State University (WSU) has been an active institutional member of the Southwest Oncology Group for over 30 years, enrolling over 4000 patients onto clinical trials. Over these years, our faculty have played an important role in support of SWOG, by providing leadership in the administrative and scientific functions of SWOG, and also by meeting and exceeding patient accrual goals in a continuous and consistent manner. Thus, WSU has remained in the first quartile of institution's performance evaluation conducted by SWOG in each of the last five years. The clinical research program in cancer at WSU has been organized along the lines of multidisciplinary disease oriented studies and in a manner that resembles the organ committee orientation of SWOG. Thus, our faculty's representation in scientific SWOG committees is constituted by individuals with expertise and commitment toward those areas of research. Accordingly, the translation of ideas into SWOG studies as well as the incorporation of SWOG studies and those of NCI designated high priority trials into WSU treatment priorities, are easily facilitated. In addition, the demographics of our region and the commitment of investigators to make clinical trials available to all patients, is clearly identified in our recruitment of minorities (27%) and women (61%) into SWQG clinical trials. The SWOG membership in WSU and the diversity of disciplinary involvement by our faculty has continued to grow over the years. To date over 100 WSU members are currently serving on over 40 committees. Similarly, 50 SWOG studies list a WSU member as a study primary coordinator or co-coordinator since the last competing application was submitted. Fifth three abstracts and 56 manuscripts have had WSU faculty as primary or co-authors. Six WSU physician faculty and 3 nurses hold 14 committee administrative roles. Since the last competitive renewal WSU has been awarded NCl supplemental grants for chemoprevention and minority recruitment. Dr. Lawrence Flaherty, a SWOG member since 1986 and Vice-Chairman of the SWOG Melanoma Committee, has been the Principal Investigator since 1996 and has maintained the prominence of WSU as a SWOG member institution.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA014028-31
Application #
6720549
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1978-01-01
Project End
2009-12-31
Budget Start
2004-04-01
Budget End
2004-12-31
Support Year
31
Fiscal Year
2004
Total Cost
$162,203
Indirect Cost
Name
Wayne State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
Moots, Paul L; O'Neill, Anne; Londer, Harold et al. (2018) Preradiation Chemotherapy for Adult High-risk Medulloblastoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4397). Am J Clin Oncol 41:588-594
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Agarwala, Sanjiv S; Lee, Sandra J; Yip, Waiki et al. (2017) Phase III Randomized Study of 4 Weeks of High-Dose Interferon-?-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Gro J Clin Oncol 35:885-892
Wozniak, Antoinette J; Moon, James; Thomas Jr, Charles R et al. (2015) A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer 16:340-7
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Gonsalves, Wilson I; Mahoney, Michelle R; Sargent, Daniel J et al. (2014) Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. J Natl Cancer Inst 106:
Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8

Showing the most recent 10 out of 215 publications